VISIPAQUE Side Effects

7018457-9 | Anaphylactoid Shock, Arteriospasm Coronary
on Sep 16, 2010 Male patient from FRANCE , 47 years of age, was diagnosed with acute coronary syndrome and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: anaphylactoid shock, arteriospasm coronary. Visipaque dosage: 60 Ml, Single Dose, I.a.. During the same period patient was treated with BIVALIRUDIN (I.v.) (View Bivalirudin Review and Bivalirudin Label ), MIDAZOLAM HYDROCHLORIDE (2 Mg, I.v.) (View Midazolam Hydrochloride Review and Midazolam Hydrochloride Label ), PLAVIX (View Plavix Review and Plavix Label ), VERAPAMIL HYDROCHLORIDE (ISOPTINE) (View Verapamil Hydrochloride (isoptine) Review and Verapamil Hydrochloride (isoptine) Label ), ISOSORBIDE DINITRATE (View Isosorbide Dinitrate Review and Isosorbide Dinitrate Label ), HEPARIN SODIUM (View Heparin Sodium Review and Heparin Sodium Label ).

6986114-0 | Erythema, Skin Necrosis
Patient was taking Visipaque (View Usage). Patient had the following side effects: erythema, skin necrosis on Sep 03, 2010 from FRANCE Additional patient health information: Female patient , 69 years of age, was diagnosed with postoperative care and. Visipaque dosage: Nr, Single Dose, I.v..

6962152-9 | Cardiac Arrest, Disorientation, Faecal Incontinence, Lethargy, Nausea, Rash, Respiratory Distress, Sinus Bradycardia
Adverse event was reported on Sep 01, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: 160ml) was diagnosed with angiogram, angioplasty (What is angioplasty?) and. Location: UNITED STATES , 64 years of age, weighting 150.0 lb, After Visipaque was administered, patient had the following side effects: cardiac arrest (What is cardiac arrest?), disorientation, faecal incontinence, lethargy, nausea (What is nausea?), rash (What is rash?), respiratory distress, sinus bradycardia. Patient was hospitalized.

6917569-5 | Coordination Abnormal, Gait Disturbance, Guillain-barre Syndrome, Hypersensitivity, Mechanical Ileus, Mental Disorder, Neuralgia, Polyneuropathy, Pruritus
on Jul 29, 2010 Female patient from DENMARK , 59 years of age, was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: coordination abnormal, gait disturbance, guillain-barre syndrome (What is guillain-barre syndrome?), hypersensitivity, mechanical ileus, mental disorder, neuralgia, polyneuropathy, pruritus. Visipaque dosage: Single Dose, I.a.. During the same period patient was treated with FELODIPINE (View Felodipine Review and Felodipine Label ), ENALAPRIL (CORODIL) (View Enalapril (corodil) Review and Enalapril (corodil) Label ), SALURES K (CENTYL MED KALIUMKLORID) (View Salures-k (centyl Med Kaliumklorid) Review and Salures-k (centyl Med Kaliumklorid) Label ), SEROQUEL (View Seroquel Review and Seroquel Label ), CITALOPRAM (AKARIN) (View Citalopram (akarin) Review and Citalopram (akarin) Label ). Patient was hospitalized and became disabled.


6917322-2 | Bradycardia, Brain Stem Infarction, Cerebral Infarction, Coma, Convulsion, Hypotension, Pneumonia, Pulmonary Mass, Renal Failure Acute
on Jul 23, 2010 Male patient from UNITED STATES , 79 years of age, was diagnosed with cough and was treated with Visipaque (View Usage). Patient had the following side effects: bradycardia, brain stem infarction, cerebral infarction, coma, convulsion, hypotension, pneumonia (What is pneumonia?), pulmonary mass, renal failure acute. Visipaque dosage: 100 Ml, Single Dose, I.v.. During the same period patient was treated with GLYBURIDE (View Glyburide Review and Glyburide Label ), METFORMIN (View Metformin Review and Metformin Label ), ZOCOR (View Zocor Review and Zocor Label ). Patient was hospitalized.

6917286-1 | Chills, Pyrexia
Patient was taking Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: chills, pyrexia on Jul 24, 2010 from INDIA Additional patient health information: Male patient , 76 years of age, weighting 396.8 lb, was diagnosed with cardiac function test and. Visipaque dosage: 90 Ml, Single Dose, I.v.. During the same period patient was treated with ANTIHYPERTENSIVE TREATMENT (View Antihypertensive Treatment Review and Antihypertensive Treatment Label ), ANTI DIABETIC TREATMENT (View Anti-diabetic Treatment Review and Anti-diabetic Treatment Label ), ANTI DIABETIC TREATMENT (View Anti-diabetic Treatment Review and Anti-diabetic Treatment Label ). Patient was hospitalized.

6907252-4 | Chills, Pyrexia
Adverse event was reported on Jul 24, 2010 by a Male patient taking Visipaque (View Usage) (Dosage: 90 Ml, Single Dose, I.v.) was diagnosed with cardiac function test and. Location: INDIA , 76 years of age, weighting 396.8 lb, Patient experienced the following unwanted or unexpected effects: chills, pyrexia. Patient was hospitalized.

6902549-6 | Pancreatitis Acute
on Jul 20, 2010 Female patient from UNITED STATES , 50 years of age, was diagnosed with medical device complication and was treated with Visipaque (View Usage). Patient had the following side effects: pancreatitis acute. Visipaque dosage: 125 Ml, Single Dose, I.v.. Patient was hospitalized.

6902548-4 | Pancreatitis Acute
on Jul 20, 2010 Male patient from UNITED STATES , 35 years of age, was diagnosed with arteriovenous fistula thrombosis and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: pancreatitis acute. Visipaque dosage: Single Dose. Patient was hospitalized.

6900596-1 | Erythema, Skin Necrosis
Patient was taking Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: erythema, skin necrosis on Jul 20, 2010 from FRANCE Additional patient health information: Female patient , 69 years of age, was diagnosed with postoperative care and. Visipaque dosage: Nr, Single Dose.

6895158-9 | Heart Rate Increased, Lethargy, Pancreatitis Acute, Pancreatitis Necrotising
Adverse event was reported on Jul 20, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: , Single Dose, I.v.) was diagnosed with medical device complication and. Location: UNITED STATES , 50 years of age, Patient had the following side effects: heart rate increased, lethargy, pancreatitis acute, pancreatitis necrotising. Patient was hospitalized.

6894280-0 | Pruritus, Toxic Skin Eruption
on Jul 20, 2010 Male patient from FRANCE , 77 years of age, was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: pruritus, toxic skin eruption. Visipaque dosage: Single Dose, I.v.. During the same period patient was treated with PLAVIX (View Plavix Review and Plavix Label ), PRASUGREL (EFIENT) (View Prasugrel (efient) Review and Prasugrel (efient) Label ).

6839178-9 | Agitation, Aphonia, Chest Discomfort, Eyelid Function Disorder, Headache, Hypoaesthesia, Musculoskeletal Pain
on Feb 03, 2010 Male patient from UNITED STATES , 50 years of age, weighting 230.0 lb, was diagnosed with chest discomfort, dyspnoea and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: agitation, aphonia, chest discomfort, eyelid function disorder, headache (What is headache?), hypoaesthesia, musculoskeletal pain. Visipaque dosage: 140 Ml, Single Dose, I.a.. During the same period patient was treated with ESOMEPRAZOLE MAGNESIUM (NEXIUM) (View Esomeprazole Magnesium (nexium) Review and Esomeprazole Magnesium (nexium) Label ). Patient was hospitalized.

6839177-7 | Anaphylactoid Shock, Cardio-respiratory Arrest, Dyspnoea, Heart Rate Increased, Pruritus, Throat Tightness
Patient was taking Visipaque (View Usage). Patient had the following side effects: anaphylactoid shock, cardio-respiratory arrest, dyspnoea, heart rate increased, pruritus, throat tightness on Jun 25, 2010 from UNITED STATES Additional patient health information: Male patient , 83 years of age, weighting 152.0 lb, was diagnosed with percutaneous coronary intervention and. Visipaque dosage: 200 Ml, Single Dose, I.a.. During the same period patient was treated with ANGIOMAX (View Angiomax Review and Angiomax Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ), VERSED (View Versed Review and Versed Label ), FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ).

6839176-5 | Anaphylactoid Reaction, Dyspnoea, Eye Swelling, Feeling Hot, Hypoaesthesia Oral, Lacrimation Increased, Loss Of Consciousness, Paraesthesia Oral, Respiratory Rate Increased
Adverse event was reported on Dec 30, 2009 by a Female patient taking Visipaque (View Usage) (Dosage: 140 Ml, Single Dose, I.v.) was diagnosed with adrenal disorder and. Location: UNITED STATES , 80 years of age, After Visipaque was administered, patient had the following side effects: anaphylactoid reaction, dyspnoea, eye swelling, feeling hot, hypoaesthesia oral, lacrimation increased, loss of consciousness, paraesthesia oral, respiratory rate increased.

6839175-3 | Blood Creatinine Increased, Blood Glucose Increased, Dyspnoea, Hypersensitivity, Purpura, White Blood Cell Count Increased
on Sep 28, 2009 Male patient from UNITED STATES , 64 years of age, was diagnosed with chest pain (What is chest pain?) and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, blood glucose increased, dyspnoea, hypersensitivity, purpura, white blood cell count increased. Visipaque dosage: 115 Ml, Single Dose, I.v.. During the same period patient was treated with METFORMIN (View Metformin Review and Metformin Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), MORNIFLUMATE (FLOMAX) (View Morniflumate (flomax) Review and Morniflumate (flomax) Label ), TERAZOSIN HCL (View Terazosin Hcl Review and Terazosin Hcl Label ), SINEMET (View Sinemet Review and Sinemet Label ), ALLEGRA (View Allegra Review and Allegra Label ), ZOCOR (View Zocor Review and Zocor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ). Patient was hospitalized.

6839173-X | Anaphylactoid Reaction, Convulsion, Dyspnoea
on Jul 31, 2009 Male patient from UNITED STATES , 68 years of age, was diagnosed with prostate cancer (What is prostate cancer?) and was treated with Visipaque (View Usage). Patient had the following side effects: anaphylactoid reaction, convulsion, dyspnoea. Visipaque dosage: 100 Ml, Single Dose, I.v.. During the same period patient was treated with EPINEPHRINE (View Epinephrine Review and Epinephrine Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ), AMLODIPINE AND VALSARTAN (EXFORGE) (View Amlodipine And Valsartan (exforge) Review and Amlodipine And Valsartan (exforge) Label ), LOVASTATIN (View Lovastatin Review and Lovastatin Label ).

6839172-8 | Atrial Fibrillation, Blood Creatinine Increased, Chest Discomfort, Dyspnoea, Hypotension, Oliguria, Renal Failure Acute
Patient was taking Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?), blood creatinine increased, chest discomfort, dyspnoea, hypotension, oliguria, renal failure acute on Jul 23, 2009 from UNITED STATES Additional patient health information: Female patient , 89 years of age, weighting 165.4 lb, was diagnosed with chest pain (What is chest pain?) and. Visipaque dosage: 110 Mg, Three Times, I.v.. During the same period patient was treated with ACETYLSALICYLIC ACID (View Acetylsalicylic Acid Review and Acetylsalicylic Acid Label ), BIVALIRUDIN (View Bivalirudin Review and Bivalirudin Label ), ALPRAZOLAM (View Alprazolam Review and Alprazolam Label ), PHENYLEPHRINE HYDROCHLORIDE (NEO SYNEOPHINE) (View Phenylephrine Hydrochloride (neo-syneophine) Review and Phenylephrine Hydrochloride (neo-syneophine) Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), LACTOBACILLUS ACIDOPHILUS (View Lactobacillus Acidophilus Review and Lactobacillus Acidophilus Label ). Patient was hospitalized.

6839171-6 | Anaphylactoid Shock, Blood Pressure Decreased, Chest Discomfort, Cough, Dyspnoea, Hyperhidrosis, Increased Upper Airway Secretion, Pulmonary Oedema, Ventricular Fibrillation
Adverse event was reported on Jul 01, 2009 by a Male patient taking Visipaque (View Usage) (Dosage: 100 Ml, Single Dose, I.v.) was diagnosed with non-hodgkin's lymphoma and. Location: UNITED STATES , 84 years of age, Patient experienced the following unwanted or unexpected effects: anaphylactoid shock, blood pressure decreased, chest discomfort, cough, dyspnoea, hyperhidrosis, increased upper airway secretion, pulmonary oedema, ventricular fibrillation.

6839139-X | Renal Failure Acute
on May 21, 2009 Male patient from UNITED STATES , 80 years of age, weighting 189.6 lb, was diagnosed with chest discomfort, dyspnoea and was treated with Visipaque (View Usage). Patient had the following side effects: renal failure acute. Visipaque dosage: 150 Ml, Single Dose, I.v.. During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), BIVALIRUDIN (View Bivalirudin Review and Bivalirudin Label ), CLONIDINE (View Clonidine Review and Clonidine Label ), HYDROMORPHONE HYDROCHLORIDE (View Hydromorphone Hydrochloride Review and Hydromorphone Hydrochloride Label ), MIDAZOLAM HYDROCHLORIDE (View Midazolam Hydrochloride Review and Midazolam Hydrochloride Label ). Patient was hospitalized.

6839138-8 | Renal Failure Acute
on May 21, 2009 Male patient from UNITED STATES , 70 years of age, was diagnosed with venous insufficiency and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: renal failure acute. Visipaque dosage: 90 Ml, Single Dose, I.v..

6822074-0 | Rash Erythematous, Rash Maculo-papular, Vasculitis
Patient was taking Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: rash erythematous, rash maculo-papular, vasculitis (What is vasculitis?) on Jun 22, 2010 from PORTUGAL Additional patient health information: Male patient , 77 years of age, . Visipaque dosage: Single Dose, I.v.. Patient was hospitalized.

6814560-4 | Road Traffic Accident
Adverse event was reported on Jun 22, 2010 by a Male patient taking Visipaque (View Usage) (Dosage: 120 Ml, Single Dose, I.v.) was diagnosed with road traffic accident and. Location: FRANCE , 16 years of age, Patient had the following side effects: road traffic accident.

6800986-1 | Amaurosis, Anuria, Cerebral Atrophy, Delirium, Leukoaraiosis, Loss Of Consciousness, Toxic Encephalopathy
on Jun 16, 2010 Female patient from NORWAY , 62 years of age, was diagnosed with cerebrovascular accident, coronary artery stenosis and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: amaurosis, anuria, cerebral atrophy, delirium, leukoaraiosis, loss of consciousness, toxic encephalopathy. Visipaque dosage: 80 Ml, Single Dose, Coronary; 60 Ml, Single Dose, I.v.. Patient was hospitalized.

6772231-7 | Chills, Hypersensitivity, Pyrexia
on Jun 03, 2010 Male patient from INDIA , 41 years of age, was diagnosed with postoperative care and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: chills, hypersensitivity, pyrexia. Visipaque dosage: 80 Mg, Single Dose, I.v.. During the same period patient was treated with METOPROLOL (BETALOC) (View Metoprolol (betaloc) Review and Metoprolol (betaloc) Label ). Patient was hospitalized.

6767280-9 | Blood Pressure Increased, Bradycardia, Coma, Condition Aggravated, Convulsion, Dialysis, Pneumonia, Pulmonary Mass, Renal Failure Acute
Patient was taking Visipaque (View Usage). Patient had the following side effects: blood pressure increased, bradycardia, coma, condition aggravated, convulsion, dialysis (What is dialysis?), pneumonia (What is pneumonia?), pulmonary mass, renal failure acute on Jun 01, 2010 from UNITED STATES Additional patient health information: Male patient , 79 years of age, was diagnosed with cough and. Visipaque dosage: 100 Ml, Single Dose, I.v.. During the same period patient was treated with GLYBURIDE (View Glyburide Review and Glyburide Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), ZOCOR (View Zocor Review and Zocor Label ).

6759504-9 | Altered State Of Consciousness, Amaurosis, Anuria, Blood Creatinine Increased, Cerebral Atrophy, Delirium, Embolic Stroke
Adverse event was reported on May 20, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: 80 Ml, Single Dose, I.a.; 60 Ml, Single Dose, I.v.) was diagnosed with cerebrovascular accident, coronary artery stenosis and. Location: NORWAY , 62 years of age, After Visipaque was administered, patient had the following side effects: altered state of consciousness, amaurosis, anuria, blood creatinine increased, cerebral atrophy, delirium, embolic stroke. Patient was hospitalized.

6759503-7 | Contrast Media Reaction, Infusion Site Erythema, Infusion Site Extravasation, Infusion Site Induration, Infusion Site Oedema
on May 21, 2010 Male patient from FRANCE , child 7 years of age, was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: contrast media reaction, infusion site erythema, infusion site extravasation, infusion site induration, infusion site oedema. Visipaque dosage: 30 Ml, Singe Dose, Extravasation.

6759502-5 | Toxic Skin Eruption
on May 21, 2010 Male patient from FRANCE , 24 years of age, was diagnosed with therapeutic embolisation and was treated with Visipaque (View Usage). Patient had the following side effects: toxic skin eruption. Visipaque dosage: Single Dose, I.a.. During the same period patient was treated with NIMODIPINE (P.o.) (View Nimodipine Review and Nimodipine Label ), IOMERON 150 (Single Dose, I.v.) (View Iomeron-150 Review and Iomeron-150 Label ), KEPPRA (500 Mg, P.o.) (View Keppra Review and Keppra Label ), PARACETAMOL (PERFALGAN) (View Paracetamol (perfalgan) Review and Paracetamol (perfalgan) Label ), HEPARIN (View Heparin Review and Heparin Label ). Patient was hospitalized.

6734108-2 | Blood Creatinine Increased, Bradycardia, Coma, Convulsion, Dialysis, Unresponsive To Stimuli, Vomiting
Patient was taking Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: blood creatinine increased, bradycardia, coma, convulsion, dialysis (What is dialysis?), unresponsive to stimuli, vomiting on May 06, 2010 from UNITED STATES Additional patient health information: Male patient , 79 years of age, was diagnosed with cough and. Visipaque dosage: 100 Ml, Single Dose, I.v.. During the same period patient was treated with GLYBURIDE (View Glyburide Review and Glyburide Label ), METFORMIN (View Metformin Review and Metformin Label ), ZOCOR (View Zocor Review and Zocor Label ).

6730607-8 | Cerebellar Ataxia, Cerebrovascular Accident, Contrast Media Reaction, Diplopia, Ophthalmoplegia, Vith Nerve Paralysis
Adverse event was reported on May 05, 2010 by a Male patient taking Visipaque (View Usage) (Dosage: Single Dose, I.a.) was diagnosed with coronary artery disease (What is coronary artery disease?) and. Location: NORWAY , 73 years of age, Patient experienced the following unwanted or unexpected effects: cerebellar ataxia, cerebrovascular accident, contrast media reaction, diplopia, ophthalmoplegia, vith nerve paralysis. During the same period patient was treated with LIDOCAINE 2% (View Lidocaine 2% Review and Lidocaine 2% Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), DILTIAZEM HYDROCHLORIDE (View Diltiazem Hydrochloride Review and Diltiazem Hydrochloride Label ), CARBOCISTEINE (View Carbocisteine Review and Carbocisteine Label ), CLOPIDOGREL (View Clopidogrel Review and Clopidogrel Label ), DIAZEPAM (View Diazepam Review and Diazepam Label ), ISOSORBIDE DINITRATE (View Isosorbide Dinitrate Review and Isosorbide Dinitrate Label ). Patient was hospitalized.

6729835-7 | Cerebrovascular Accident, Cranial Nerve Paralysis
on May 05, 2010 Female patient from NORWAY , 88 years of age, was treated with Visipaque (View Usage). Patient had the following side effects: cerebrovascular accident, cranial nerve paralysis. Visipaque dosage: Single Dose, I.a.. During the same period patient was treated with HEPARIN SODIUM (I.a.) (View Heparin Sodium Review and Heparin Sodium Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), CLOPIDOGREL (View Clopidogrel Review and Clopidogrel Label ), DIDOCAINE 2% (View Didocaine 2% Review and Didocaine 2% Label ), BIVALIRUDIN (View Bivalirudin Review and Bivalirudin Label ), GLYCERYL TRINITRATE (View Glyceryl Trinitrate Review and Glyceryl Trinitrate Label ), ISOSORBIDE DINITRATE (View Isosorbide Dinitrate Review and Isosorbide Dinitrate Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

6729833-3 | Arthritis, Fall, Foot Deformity, Nausea, Neuropathy Peripheral, Pain
on May 06, 2010 Female patient from DENMARK , 63 years of age, was diagnosed with non-small cell lung cancer and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: arthritis (What is arthritis?), fall (What is fall?), foot deformity, nausea (What is nausea?), neuropathy peripheral, pain (What is pain?). Visipaque dosage: 144 Ml, Single Dose; Single Dose; Iv. During the same period patient was treated with TAXOL (View Taxol Review and Taxol Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ).

6722782-6 | Cerebrovascular Accident
Patient was taking Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident on May 03, 2010 from NORWAY Additional patient health information: Female patient , 64 years of age, weighting 160.9 lb, was diagnosed with coronary artery disease (What is coronary artery disease?), intravenous catheter management and. Visipaque dosage: Single Dose, I.a.. During the same period patient was treated with HEPARIN SODIUM (I.a.) (View Heparin Sodium Review and Heparin Sodium Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ), BENDROFLUAZIDE (View Bendrofluazide Review and Bendrofluazide Label ), FLUTICASONE PROPIONATE MICRONISED (FLIXONASE) (View Fluticasone Propionate Micronised (flixonase) Review and Fluticasone Propionate Micronised (flixonase) Label ), GLYCERYL TRINITRATE (View Glyceryl Trinitrate Review and Glyceryl Trinitrate Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ). Patient was hospitalized.

6720709-4 | Respiratory Disorder
Adverse event was reported on Apr 29, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: 50 Ml, Single Dose, Iv) . Location: SPAIN , 30 years of age, weighting 114.6 lb, Patient had the following side effects: respiratory disorder. Patient was hospitalized.

6682027-2 | Pruritus, Rash, Skin Disorder, Wound
on Apr 14, 2010 Female patient from UNITED STATES , 37 years of age, weighting 135.8 lb, was diagnosed with computerised tomogram and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: pruritus, rash (What is rash?), skin disorder, wound (What is wound?). Visipaque dosage: 100 Ml One Dose Iv Bolus. Patient was hospitalized.

6667814-9 | Hallucination
on Mar 29, 2010 Female patient from SPAIN , 60 years of age, was diagnosed with allergy prophylaxis and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: hallucination. Visipaque dosage: Single Dose. During the same period patient was treated with PREDNISONA (View Prednisona Review and Prednisona Label ), POLARAMINE (View Polaramine Review and Polaramine Label ), ATENOLOL (BLOKIUM DIU) (View Atenolol (blokium-diu) Review and Atenolol (blokium-diu) Label ), ACETYLSALICYLIC ACID SRT (View Acetylsalicylic Acid Srt Review and Acetylsalicylic Acid Srt Label ).

6667798-3 | Resuscitation, Unresponsive To Stimuli
Patient was taking Visipaque (View Usage). Patient had the following side effects: resuscitation, unresponsive to stimuli on Mar 25, 2010 from CANADA Additional patient health information: Female patient , 72 years of age, was diagnosed with angiopathy and. Visipaque dosage: 36 Ml, Single Dose, I.a.. During the same period patient was treated with VERSED (View Versed Review and Versed Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ).

6664743-1 | Unresponsive To Stimuli
Adverse event was reported on Mar 19, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: 36 Ml, Single Dose, I.a.) was diagnosed with angiopathy and. Location: CANADA , 72 years of age, After Visipaque was administered, patient had the following side effects: unresponsive to stimuli. During the same period patient was treated with VERSED (View Versed Review and Versed Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ).

6640105-8 | Toxic Skin Eruption
on Mar 05, 2010 Male patient from FRANCE , 24 years of age, was diagnosed with therapeutic embolisation and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: toxic skin eruption. Visipaque dosage: Single Dose, I.a.. During the same period patient was treated with NIMOPIDINE (NIMOTOP) (View Nimopidine (nimotop) Review and Nimopidine (nimotop) Label ), IOMERON 150 (Single Dose, I.v.) (View Iomeron-150 Review and Iomeron-150 Label ), KEPPRA (500 Mg, P.o.) (View Keppra Review and Keppra Label ), PARACETAMOL (PERFALGAN) (View Paracetamol (perfalgan) Review and Paracetamol (perfalgan) Label ), HEPARIN (View Heparin Review and Heparin Label ). Patient was hospitalized.

6637086-X | Acute Pulmonary Oedema, Anuria, Cardiac Fibrillation, Cardio-respiratory Arrest, Cardiogenic Shock, Coagulation Test Abnormal, Coma, Disseminated Intravascular Coagulation
on Mar 03, 2010 Male patient from FRANCE , weighting 8.82 lb, was diagnosed with lymphocele and was treated with Visipaque (View Usage). Patient had the following side effects: acute pulmonary oedema, anuria, cardiac fibrillation, cardio-respiratory arrest, cardiogenic shock, coagulation test abnormal, coma, disseminated intravascular coagulation. Visipaque dosage: 20 Ml, Single Dose, Body Cavity. During the same period patient was treated with HETASTARCH (VOLUVEN) (View Hetastarch (voluven) Review and Hetastarch (voluven) Label ), ALBUMIN (HUMAN) (View Albumin (human) Review and Albumin (human) Label ), CEFAZOLIN (View Cefazolin Review and Cefazolin Label ).

6637085-8 | Anaemia Macrocytic, Confusional State, Hyperkalaemia, Lactic Acidosis, Renal Failure Acute
Patient was taking Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: anaemia macrocytic, confusional state, hyperkalaemia, lactic acidosis, renal failure acute on Mar 04, 2010 from FRANCE Additional patient health information: Male patient , 71 years of age, . Visipaque dosage: Single Dose, I.v.. During the same period patient was treated with GLUCOPHAGE (P.o.) (View Glucophage Review and Glucophage Label ), RAMIPRIL (P.o.) (View Ramipril Review and Ramipril Label ), LASIX L 60 MG (P.o.) (View Lasix-l 60 Mg Review and Lasix-l 60 Mg Label ), ATORVASTATIN CALCIUM (P.o.) (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), ISOPTIN (View Isoptin Review and Isoptin Label ), PLAVIX (View Plavix Review and Plavix Label ), CARDENSIEL (View Cardensiel Review and Cardensiel Label ), PREVISCAN (View Previscan Review and Previscan Label ). Patient was hospitalized.

6626677-8 | Headache, Meningism, Meningitis, Musculoskeletal Stiffness, Phonophobia, Tinnitus, Vomiting
Adverse event was reported on Feb 26, 2010 by a Female patient taking Visipaque (View Usage) (Dosage: 20 Ml, Single Dose, I.t.) . Location: FRANCE , 46 years of age, Patient experienced the following unwanted or unexpected effects: headache (What is headache?), meningism, meningitis (What is meningitis?), musculoskeletal stiffness, phonophobia, tinnitus (What is tinnitus?), vomiting. During the same period patient was treated with LEVOTHYROX (View Levothyrox Review and Levothyrox Label ), TRUVADA (View Truvada Review and Truvada Label ), LEVEMIR (View Levemir Review and Levemir Label ), LYRICA (View Lyrica Review and Lyrica Label ).

6626676-6 | Septic Shock
on Feb 26, 2010 Female patient from KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF , 72 years of age, was diagnosed with back pain (What is back pain?) and was treated with Visipaque (View Usage). Patient had the following side effects: septic shock. Visipaque dosage: 50 Ml, Single Dose, I. A..

6623904-8 | Hepatitis Toxic, Hypersensitivity
on Feb 22, 2010 Female patient from NORWAY , 50 years of age, was diagnosed with occipital neuralgia and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: hepatitis toxic, hypersensitivity. Visipaque dosage: 100 Ml, Single Dose, I .v.. During the same period patient was treated with CARBAMAZEPINE (600 Mg, P.o.) (View Carbamazepine Review and Carbamazepine Label ), DROSPIRENONE AND ETHINYL ESTRADIOL (View Drospirenone And Ethinyl Estradiol Review and Drospirenone And Ethinyl Estradiol Label ). Patient was hospitalized.

6615098-X | Anaemia Macrocytic, Confusional State, Hyperkalaemia, Lactic Acidosis, Renal Failure Acute, Unevaluable Event
Patient was taking Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia macrocytic, confusional state, hyperkalaemia, lactic acidosis, renal failure acute, unevaluable event on Feb 18, 2010 from FRANCE Additional patient health information: Male patient , 71 years of age, . Visipaque dosage: Single Dose, I.v.. During the same period patient was treated with RAMIPRIL (P.o.) (View Ramipril Review and Ramipril Label ), LASIX L 60 MG (P.o.) (View Lasix-l 60 Mg Review and Lasix-l 60 Mg Label ), GLUCOPHAGE (P.o.) (View Glucophage Review and Glucophage Label ), ATORVASTATIN CALCIUM (P.o.) (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), ISOPTIN (View Isoptin Review and Isoptin Label ), PLAVIX (View Plavix Review and Plavix Label ), CARDENSIEL (View Cardensiel Review and Cardensiel Label ), PREVISCAN (View Previscan Review and Previscan Label ). Patient was hospitalized.

6592722-1 | Chills, Contrast Media Reaction, Dizziness, Pyrexia
Adverse event was reported on Feb 02, 2010 by a Male patient taking Visipaque (View Usage) (Dosage: 80 Ml, Single Dose, I.v.) . Location: NORWAY , 29 years of age, weighting 165.3 lb, Patient had the following side effects: chills, contrast media reaction, dizziness (What is dizziness?), pyrexia.

6589531-6 | Anuria, Dialysis, Hepatitis, Pancytopenia, Paraplegia
on Feb 04, 2010 Male patient from THAILAND , 75 years of age, was diagnosed with colon cancer, flatulence and was treated with Visipaque (View Usage). After Visipaque was administered, patient had the following side effects: anuria, dialysis (What is dialysis?), hepatitis (What is hepatitis?), pancytopenia, paraplegia. Visipaque dosage: 100 Ml, Single Dose, I.v.. Patient was hospitalized.

6589388-3 | Diplopia, Embolism, Post Procedural Complication
on Jan 27, 2010 Male patient from NORWAY , 62 years of age, was diagnosed with acute coronary syndrome and was treated with Visipaque (View Usage). Patient experienced the following unwanted or unexpected effects: diplopia, embolism, post procedural complication. Visipaque dosage: Single Dose, I.a.. Patient was hospitalized.

6589374-3 |
Patient was taking Visipaque (View Usage). on Jan 27, 2010 from NORWAY Additional patient health information: Male patient , 67 years of age, . Visipaque dosage: .